Needham Maintains Buy on RxSight, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Needham analyst David Saxon maintains a Buy rating on RxSight (NASDAQ:RXST) and raises the price target from $64 to $75.
May 07, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst David Saxon reaffirms a Buy rating on RxSight and increases the price target from $64 to $75, indicating a positive outlook.
The increase in price target by a reputable analyst suggests a strong belief in RxSight's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100